Market capitalization | $997.47m |
Enterprise Value | $-53.03m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.12 |
EV/Sales (TTM) EV/Sales | -0.67 |
P/S ratio (TTM) P/S ratio | 12.65 |
P/B ratio (TTM) P/B ratio | 0.70 |
Revenue growth (TTM) Revenue growth | -83.93% |
Revenue (TTM) Revenue | $78.88m |
As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.
9 Analysts have issued a Vir Biotechnology Inc forecast:
9 Analysts have issued a Vir Biotechnology Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 79 79 |
84%
84%
|
|
Gross Profit | 58 58 |
87%
87%
|
|
EBITDA | -492 -492 |
83%
83%
|
EBIT (Operating Income) EBIT | -512 -512 |
76%
76%
|
Net Profit | -483 -483 |
84%
84%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Marianne Backer |
Employees | 587 |
Founded | 2016 |
Website | www.vir.bio |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.